
Last updated: 2026-09-09 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Septerna, Inc. (SEPN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $37.37, with a market capitalization of $1.72B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.67 to $51.10. This page covers its latest market performance, valuation, price trends and company information.
$1.72B | |
$37.37 | |
$51.10 | |
$4.17 | |
$37.37 | |
13.00 | |
439.99K | |
-- | |
$51.10 | |
$13.67 | |
-- | |
-- |
Septerna, Inc. (SEPN) is trading at $37.37 in pre-market trading as of 2026-09-09 11:01:00, unchanged from the previous close of $37.37
Pre-market trading shows how investors are pricing SEPN before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Septerna, Inc. (SEPN) moved from $38.91 to $37.37, representing a decline of 3.96% ($1.54).
The stock traded between $36.01 and $40.95 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 297.08 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63.3%
SEPN is currently trading at $37.37, placing it 63.3% of the way from its 52-week low of $13.67 to its 52-week high of $51.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Septerna, Inc. (SEPN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.